

Christoph Kapitza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7037194/publications.pdf>

Version: 2024-02-01

19
papers

815
citations

840119

11
h-index

839053

18
g-index

19
all docs

19
docs citations

19
times ranked

886
citing authors

#	ARTICLE	IF	CITATIONS
1	Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. <i>Diabetes Care</i> , 2015, 38, 1263-1273.	4.3	216
2	Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 258-266.	1.1	135
3	Semaglutide, a once-a-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 497-504.	1.0	117
4	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. <i>Diabetologia</i> , 2017, 60, 1390-1399.	2.9	68
5	The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. <i>Advances in Therapy</i> , 2011, 28, 213-226.	1.3	67
6	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1789-1798.	2.2	49
7	The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. <i>Advances in Therapy</i> , 2011, 28, 650-660.	1.3	27
8	Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1369-1377.	1.0	24
9	Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 622-627.	2.2	24
10	Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2137-2145.	4.3	21
11	Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 951-955.	1.0	12
12	Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 278-284.	2.4	12
13	Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 599-611.	2.2	10
14	Impact of insulin glargine and lixisenatide on β -cell function in patients with type 2 diabetes mellitus: randomized open-label study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1625-1629.	2.2	9
15	Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2344-2353.	2.2	8
16	Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog [®] in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 187-195.	2.2	6
17	Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 684-692.	2.2	6
18	A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 674-681.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 806-815.	2.2	0